Showing results (131-140 of 165) with videos related to

Sort By:
Pageof 17
Nature Communications|July 21, 2019
circTP63 functions as a ceRNA to promote lung squamous cell carcinoma progression by upregulating FOXM1Zhuoan Cheng, Chengtao Yu, Shaohua Cui, et al.
The Oncologist|August 31, 2018
Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) <i>EGFR</i> Mutation-Positive Non-Small Cell Lung Cancer: A Prospective, Single-Arm, Phase II StudyLiwen Xiong, Rong Li, Jiayuan Sun, et al.
Oncotarget|May 3, 2017
PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC)Liyan Jiang, Xinying Su, Tianwei Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 16, 2019
Combination of Metformin and Gefitinib as First-Line Therapy for Nondiabetic Advanced NSCLC Patients with EGFR Mutations: A Randomized, Double-Blind Phase II TrialLi Li, Liyan Jiang, Yubo Wang, et al.
Annals of Palliative Medicine|June 8, 2022
Expert consensus on multi-disciplinary treatment, whole-course pulmonary rehabilitation management in patients with lung cancer and chronic obstructive lung diseaseXiaowei Mao, Fang Hu, Jin Peng, et al.
JTO Clinical and Research Reports|October 11, 2022
Long-Term Efficacy, Safety, and Subgroup Analysis of Savolitinib in Chinese Patients With NSCLCs Harboring <i>MET</i> Exon 14 Skipping AlterationsShun Lu, Jian Fang, Xingya Li, et al.
The Lancet. Respiratory Medicine|June 24, 2021
Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 studyShun Lu, Jian Fang, Xingya Li, et al.
JMIR Cancer|June 5, 2024
Telehealth With Comprehensive Live-Fed Real-World Data as a Patient Care Platform for Lung Cancer: Implementation and Evaluation StudyDi Zheng, Yanhong Shang, Jian Ni, et al.
Cancer Immunology, Immunotherapy : CII|October 20, 2021
Camrelizumab in different PD-L1 expression cohorts of pre-treated advanced or metastatic non-small cell lung cancer: a phase II studyJin-Ji Yang, Cheng Huang, Yun Fan, et al.
The Lancet. Respiratory Medicine|June 13, 2024
Garsorasib in patients with KRAS<sup>G12C</sup>-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trialZiming Li, Xiaomin Dang, Dingzhi Huang, et al.
Pageof 17